“遥控开关”让CAR-T细胞学会“劳逸结合”

Core Insights - A research team from the Ludwig Cancer Research Center and the Swiss Federal Institute of Technology in Lausanne has developed a method to regulate CAR-T cells on demand, as reported in the latest issue of Nature Chemical Biology. This advancement lays the groundwork for expanding such powerful therapies to more complex scenarios like solid tumor treatments, potentially benefiting more patients from precision immunotherapy [1][2]. Group 1: CAR-T Cell Therapy - CAR-T therapy has shown significant efficacy in hematological malignancies by genetically engineering patients' T cells to express chimeric antigen receptors (CARs), which can specifically target and kill cancer cells [1]. - The therapy faces challenges, including the risk of life-threatening cytokine release syndrome (CRS) and neurotoxicity due to overactive CAR-T cells, as well as functional exhaustion of CAR-T cells under continuous antigen stimulation, leading to reduced efficacy or relapse [1]. Group 2: New Regulatory Mechanism - The study introduces a simple and clinically feasible method to remotely control the already clinically used cancer drug venetoclax, which can reversibly reduce CAR-T cell activation without triggering self-destruction, allowing them to detach from cancer targets [2]. - Unlike previous controllable CAR designs, the new system utilizes only human protein components and clinically recognized non-immunosuppressive drugs to disrupt the interaction between CAR-T cells and tumor cells, providing higher safety by controlling them without sacrificing their potential for future treatments [2]. Group 3: Implications for Immunotherapy - The introduction of a "remote control switch" for CAR-T cells, using venetoclax, allows for a balance between activation and rest, enhancing the safety and effectiveness of immunotherapy. This innovation may also extend the application of CAR-T therapy to solid tumors, thereby benefiting a larger patient population [3].